PriMera Scientific Surgical Research and Practice (ISSN: 2836-0028)

Mini Research Article

Volume 7 Issue 1

A Multimodal Metabolic and Neuroendocrine Approach to Polytrauma Syndrome: A Proposed Integrative Protocol Incorporating Hyperbaric Oxygen Therapy and Hormonal Optimization

K Paul Stoller*

December 31, 2025

DOI : 10.56831/PSSRP-07-237

View PDF

Abstract

Polytrauma syndrome, particularly among military veterans and individuals with traumatic brain injury (TBI), is associated with complex neuropsychiatric, metabolic, and neuroendocrine dysfunction. Conventional treatment approaches often focus on isolated symptoms rather than underlying systems-level dysregulation. This paper proposes a comprehensive integrative clinical protocol addressing neuro-metabolic dysfunction, neuroendocrine abnormalities, and cerebral hypometabolism in patients with polytrauma syndrome. The approach integrates hormonal assessment and optimization, metabolic support, and low-pressure hyperbaric oxygen therapy (HBOT). This framework is presented as a hypothesis-generating model aimed at improving outcomes in a population with persistently high morbidity and mortality.

References

  1. McAllister TW. “Neurobiological consequences of traumatic brain injury”. Dialogues Clin Neurosci 13.3 (2011): 287-300.
  2. Stein MB., et al. “PTSD and TBI comorbidity”. Am J Psychiatry (2012).
  3. Bigler ED. “Neuroimaging biomarkers in mild traumatic brain injury (mTBI)”. Neuropsychol Rev 23.3 (2013): 169-209.
  4. Schneider HJ., et al. “Hypopituitarism after traumatic brain injury”. Lancet (2007).
  5. Bombardier CH., et al. “Suicide risk after TBI”. Arch Phys Med Rehabil (2010).
  6. Tanriverdi F., et al. “Pituitary dysfunction after brain injury”. Endocr Rev (2015).
  7. Wagner AK., et al. “Testosterone deficiency after TBI”. J Neurotrauma (2010).
  8. Agha A and Thompson CJ. “Anterior pituitary dysfunction following TBI”. Clin Endocrinol 64.5 (2006): 481-8.
  9. Meyer-Lindenberg A., et al. “Oxytocin and social cognition”. Nat Rev Neurosci (2011).
  10. Koch SBJ., et al. “Oxytocin and fear regulation”. Biol Psychiatry (2016).
  11. Flanagan JC., et al. “Oxytocin in PTSD”. Psychoneuroendocrinology (2018).
  12. Olff M. “The role of oxytocin in PTSD”. Eur J Psychotraumatol (2012).
  13. Kaminetsky J., et al. “Enclomiphene for secondary hypogonadism”. BJU Int (2013).
  14. Wiehle RD., et al. “Enclomiphene citrate restores testosterone”. Andrology (2014).
  15. Leder BZ., et al. “Effects of aromatase inhibition in elderly men with low or borderline-low serum testosterone levels”. J Clin Endocrinol Metab 89.3 (2004): 1174-80.
  16. Turner N., et al. “Berberine and its more biologically available derivative, dihydroberberine, inhibit mitochondrial respiratory complex I: a mechanism for the action of berberine to activate AMP-activated protein kinase and improve insulin action”. Diabetes 57.5 (2008): 1414-8.
  17. Yin J., et al. “Berberine meta-analysis”. Metabolism (2008).
  18. Cicero AFG., et al. “Berberine clinical effects”. Nutrients (2019).
  19. Harch PG., et al. “HBOT for chronic brain injury”. Med Gas Res (2012).
  20. Tal S., et al. “Hyperbaric oxygen neuroplasticity”. PLoS One (2015).
  21. Boussi-Gross R., et al. “HBOT in chronic TBI”. PLoS One (2013).
  22. Hadanny A., et al. “Hyperbaric oxygen therapy for brain repair”. Nat Rev Neurol (2020).
  23. Wolf EG., et al. “Low-pressure HBOT in mild TBI”. Undersea Hyperb Med (2012).
  24. Miller RS., et al. “Cerebral perfusion changes with HBOT”. J Neurotrauma (2015).
  25. Rupprecht TA., et al. “Neuroborreliosis”. Lancet Neurol (2008).
  26. Fallon BA., et al. “CNS Lyme disease”. Am J Psychiatry (1998).
  27. Jha A., et al. “Modafinil in neurological disorders”. CNS Drugs (2008).
  28. Kaiser PR., et al. “Modafinil after TBI”. J Clin Psychopharmacol (2010).
  29. Teitelman E. “Modafinil cognitive effects”. Neuropsychiatr Dis Treat (2006).